Psychological and cardiovascular effects and short-term sequelae of MDMA ('Ecstasy') in MDMA-naive healthy volunteers

Neuropsychopharmacology

Volumn 19, Issue 4, 1998, Pages 241-251

  Vollenweider, Franz X ^a   Gamma, Alex ^a   Liechti, Matthias ^a   Huber, Theo ^b  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b Department for Inner Medicine ^*  (Switzerland)

Author keywords

'Ecstasy'; Adverse effects; Body temperature; Cardiovascular effects; Entactogen; Hallucinogen; MDMA (3,4 methylenedioxymethamphetamine); Psychological effects; Serotonin; Stimulant; Stroop color naming test

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ADULT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BRUXISM; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONTROLLED STUDY; DEPERSONALIZATION; DEPTH PERCEPTION; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; EMOTION; FATIGUE; FEMALE; GAIT DISORDER; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INSOMNIA; JAW; MALE; MOOD; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOMETRY; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; RESTLESS LEGS SYNDROME; SELECTIVE ATTENTION; SENSATION; SYSTOLIC BLOOD PRESSURE; THOUGHT DISORDER; TIME PERCEPTION; WELLBEING;

ADULT; AFFECT; ANOREXIA; BLOOD PRESSURE; BODY TEMPERATURE; BRUXISM; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HALLUCINOGENS; HUMANS; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; REACTION TIME;

EID: 0031783570     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00013-X     Document Type: Article

References (54)

1. Battaglia G, Yeh SY, De Souza EB (1988): MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29:269-274
2. Carter CS, Krener P, Chaderjian M, Northcutt C, Wolfe V (1996): Abnormal processing of irrelevant information in attention deficit hyperactivity disorder. Psychiatry Res 56:59-70
3. Corcoran DWJ (1965): Personality and the inverted U-relation. Br J Psychol 56:267-273
4. Dafters RI (1994): Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology (Berlin) 114:505-508
5. Davison D, Parrott C (1997): Ecstasy (MDMA) in recreational users: Self-reported psychological and physiological effects. Hum Psychopharmacol 12:221-226
6. Dittrich A (1994): Psychological aspects of altered states of consciousness of the LSD type: Measurements of their basic dimensions and prediction of individual differences. In Pletscher A, Ladewig D (eds), 50 years of LSD. Current status and perspectives of hallucinogens. New York, Parthenon Publishing, pp 101-118
7. Dittrich A (1996): Ätiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände. Berlin, VWB - Verlag für Wissenschaft und Bildung
8. Dittrich A, von Arx S, Staub S (1985): International study on altered states of consciousness (ISASC). Summary of the results. Germ J Psych 9:319-339
9. Downing J (1986): The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18:335-340
10. Fahrenberg J, Hampel R, Selg H (1984): Das Freiburger Persönlichkeitsinventar FPI. Göttingen, Hogrefe
11. Fischer R (1954): Factors involved in drug-produced model psychoses. J Ment Sci 100:623-631
12. Fischer R, Marks PA, Hill RM, Rockey MA (1968): Personality structure as the main determinant of drug induced (model) psychoses. Nature 218:296-298
13. Geyer MA, Callaway CW (1994): Behavioral pharmacology of ring-substituted amphetamine analogs. In Cho AK, Segal DS (eds), Amphetamine and its analogs: Psychopharmacology, toxicology, and abuse. San Diego, Academic Press, pp 177-208
14. Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990): Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485-498
15. Giroud C, Augsburger M, Sadeghipour F, Varesio E, Veuthey J-L, Rivier L (1997): Ecstasy - La situation en Suisse romande. Composition des saisies, analyse des échantillons biologiques et brève revue de son action pharmacologique et de sa toxicité. Praxis 86:510-523
16. Gouzoulis E, von Bardeleben U, Rupp A, Kovar KA, Hermle L (1993): Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology 8:187-193
17. Gouzoulis E, Thelen B, Schreckenberger M, Kovar KA, Spitzer M, Sass H (1997): Human experimental neurometabolic and neuropsychological studies with psilocybin, d-methamphetamine and 3,4-methylenedioxyethylamphetamine (MDE). [Abstract] Pharmacopsychiatry 30:171
18. Granquist L (1995): Neurochemical markers and MDMA neurotoxicity. Multidisciplinary Association for Psychedelic Studies, Inc. 5:10-13
19. Green AR, Cross AJ, Goodwin GM (1996): Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxydmethamphetamine (MDMA of "Ecstasy"). Psychopharmacology (Berlin) 119:247-260
20. Greer G (1985): Using MDMA in psychotherapy. Advances 2:57-62
21. Greer G, Tolbert P (1986): Subjective reports on the effects of MDMA in a clinical setting. J Psychoactive Drugs 18:319-327
22. Grob C, Bravo G, Walsh R (1990): Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch Gen Psychiatry 47:288
23. Grob CS, Bravo GL, Walsh RN, Liester MB (1992): The MDMA-neurotoxicity controversy: Implications for clinical research with novel psychoactive drugs. J Nerv Ment Dis 180:355-356
24. Grob CS, Poland RE, Chang L, Ernst T (1996): Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans - Methodological considerations and preliminary observations. Behav Brain Res 73:103-107
25. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R (1996): Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol 20:432-440
26. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E (1993): Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8:171-176
27. Hermle L, Spitzer M, Gouzoulis E (1994): Arylalkanamine-induced effects in normal volunteers: On the significance of research in hallucinogenic agents for psychiatry. In Pletscher A, Ladewig D (eds), 50 Years of LSD. Current status and perspectives of hallucinogens. New York, London, The Parthenon Publishing Group, pp 87-99
28. Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB (1989): 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 249:713-720
29. Janke W, Debus G (1978): Die Eigenschaftswörterliste (EWL-K) - Ein Verfahren zur Erfassung der Befindlichkeit. Göttingen, Hogrefe
30. Johnson MP, Hoffman AJ, Nichols DE (1986): Effects of the enantiomeres of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269-276
31. Kemmerling K, Haller R, Hinterhuber H (1996): Das neurospychiatrische Risiko von 3,4-Methylendioxymethamphetamin ("Ecstasy"). Neuropsychiatrie 10:94-102
32. Liester MB, Grob CS, Bravo G, Walsh RN (1992): Phenomenology and sequelae of 3,4-methylendioxymetamphetamine use. J Nerv Ment Dis 180:345-352
33. MacLeod CM (1991): Half a century of research on the Stroop effect: An integrative review. Psychol Bull 109:163-203
34. McCann UD, Ricaurte GA (1991): Lasting neuropsychiatric sequelae of (±) methylenedioxymeth-amphetamine ("ecstasy") in recreational users. J Clin Psychopharmacol 11:302-305
35. McCann UD, Ricaurte GA (1992): MDMA ("ecstasy") and panic disorder: induction by a single dose. Biol Psychiatry 32:950-953
36. McGhie A, Chapman J (1961): Disorder of attention and perception in early schizophrenia. Br J Med Psychol 34:102-116
37. Nichols DE (1986): Differences between the mechanism of action of MDMA, MBDB, and the classical hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs 18:305-313
38. Pallanti S, Mazzi D (1992): MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 32:91-95
39. Peroutka SJ, Newman H, Harris H (1988): Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273-277
40. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985): Hallucinogenic amphetamines selectively destroy brain serotonin nerve terminals. Science 229:1505-1506
41. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988): Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration. Brain Res 446:165-168
42. Rupp A, Kovar KA, Beuerle G, Ruf C, Folkers G (1994): A new pharmophoric model for 5-HT reuptake-inhibitors: Differentiation of amphetamine analogues. Pharm Acta Helv 68:235-244
43. Saunders N (1995): Ecstasy and the dance culture. London, W.B. Saunders
44. Schmidt CJ (1987): Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:240-247
45. SFA/ISPA. (1996): Ecstasy in der Schweiz, die erste repräsentative Studie zur Modedroge. Lausanne, SFA (Schweizerische Fachstelle für Alkohol- und andere Drogenprobleme)
46. Shulgin AT (1986): The background and chemistry of MDMA. J Psychoactive Drugs 18:291-304
47. Solowij N, Hall W, Lee N (1992): Recreational MDMA use in Sydney: A profile of "Ecstacy" users and their experiences with the drug. Br J Addict 87:1161-1172
48. Steele TD, McCann UD, Ricaurte GA (1994): 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): Pharmacology and toxicology in animals and humans. Addiction 89:539-551
49. Strassman RJ (1995): Hallucinogenic drugs in psychiatric research and treatment. J Nerv Ment Dis 183:127-138
50. Stroop JR (1935): Studies of interference in serial and verbal reactions. J Exp Psychol 18:643
51. Vollenweider FX, Antonini A, Leenders KL, Mathys K, Angst J (1997a): Effects of high amphetamine doses on mood and cerebral glucose metabolism in normals using positron emission tomography (PET). Psychiatry Res: Neuroimaging, in press
52. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997b): Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357-372
53. von Zerssen D (1976): Manual zur Beschwerden-Liste. Weinheim, Belz
54. Whitaker Azmitia PM, Aronson TA (1989): "Ecstasy" (MDMA)-induced panic [letter]. Am J Psychiatry 146:119